The management of invasive fungal disease (IFD) in the haemato-oncology setting remains a challenge. This article reviews recent guidelines relating to IFD for their similarities and differences, as well as applying the Appraisal of Guidelines Research and Evaluation (AGREE) criteria. The guidelines’ recommendations on antifungal prophylaxis, empirical and definitive treatment of candidiasis and aspergillosis are summarized; also, minimum standards for diagnosis and follow-up are discussed. This critique of the reviewed guidelines is a practical guide to physicians and commissioners in making local policies for IFD management
This is the last of a series of articles on invasive fungal infections prepared by opinion leaders i...
Invasive fungal infection (IFI) is a persistent problem among critically ill and immunocompromised p...
This is the last of a series of articles on invasive fungal infections prepared by opinion leaders i...
The management of invasive fungal disease (IFD) in the haemato-oncology setting remains a challenge....
Patients at risk of, or diagnosed with, an invasive fungal infection benefit from an early antifunga...
AbstractInvasive fungal infections (IFIs) are life-threatening conditions that require rapid diagnos...
The introduction of novel antifungal agents for the treatment of invasive fungal disease in hematolo...
Evidence-based guidelines for the treatment of established fungal infections in the adult haematolog...
The introduction of novel antifungal agents for the treatment of invasive fungal disease in hematolo...
Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing...
Invasive fungal infections (IFI) are a major cause of morbidity and mortality in immunocompromised p...
There is a strong argument for the use of antifungal prophylaxis in high-risk patients given the sig...
Aim:This review discusses the most common used antifungal agents in the treatment of invasive fungal...
Item does not contain fulltextAntifungal prophylaxis during treatment for haematological malignancie...
Invasive fungal infection (IFI) is a serious and common complication in hematological patients. The ...
This is the last of a series of articles on invasive fungal infections prepared by opinion leaders i...
Invasive fungal infection (IFI) is a persistent problem among critically ill and immunocompromised p...
This is the last of a series of articles on invasive fungal infections prepared by opinion leaders i...
The management of invasive fungal disease (IFD) in the haemato-oncology setting remains a challenge....
Patients at risk of, or diagnosed with, an invasive fungal infection benefit from an early antifunga...
AbstractInvasive fungal infections (IFIs) are life-threatening conditions that require rapid diagnos...
The introduction of novel antifungal agents for the treatment of invasive fungal disease in hematolo...
Evidence-based guidelines for the treatment of established fungal infections in the adult haematolog...
The introduction of novel antifungal agents for the treatment of invasive fungal disease in hematolo...
Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing...
Invasive fungal infections (IFI) are a major cause of morbidity and mortality in immunocompromised p...
There is a strong argument for the use of antifungal prophylaxis in high-risk patients given the sig...
Aim:This review discusses the most common used antifungal agents in the treatment of invasive fungal...
Item does not contain fulltextAntifungal prophylaxis during treatment for haematological malignancie...
Invasive fungal infection (IFI) is a serious and common complication in hematological patients. The ...
This is the last of a series of articles on invasive fungal infections prepared by opinion leaders i...
Invasive fungal infection (IFI) is a persistent problem among critically ill and immunocompromised p...
This is the last of a series of articles on invasive fungal infections prepared by opinion leaders i...